CompletedInterventionalPhase 2Last updated Mar 5, 2019

A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis

A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in Symptomatic Subjects With Generalized Myasthenia Gravis

Overview

ClinicalTrials.gov ID: NCT02473952
Lead Sponsor: Grifols Therapeutics LLCINDUSTRY
Brief Summary: The primary objective is to evaluate whether IGIV-C improves MG symptoms as compared to placebo in subjects with MG.
Study Type: Interventional

Status

Overall Status: Completed
Start Date: Aug 2015Actual
Primary Completion Date: Jan 2018Actual
Completion Date: Jan 2018Actual

Study Record Dates

First Submitted: Jun 14, 2015
First Submitted that Met QC Criteria: Jun 16, 2015
First Posted: Jun 17, 2015Estimated
Last Update Submitted that Met QC Criteria: Mar 1, 2019
Last Update Posted: Mar 5, 2019Actual
Last Verified: Mar 2019

NCT02413580Completed

A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis Exacerbations

NCT02473965Completed

Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis

NCT00306033Completed

Intravenous Immune Globulin Treatment Compared to Placebo in Patients With Myasthenia Gravis

NCT04728425Completed

Subcutaneous Immunoglobulin for Myasthenia Gravis

NCT00515450Completed

Efficacy and Safety Study of GB-0998 for Treatment of Generalized Myasthenia Gravis

NCT03165435Withdrawn

A Study to Evaluate the Efficacy of CV-MG01 (Myasterix) in Myasthenia Gravis